3rd Annual MSK Symposium on Lymphoma
State-of-the-Art in Biology, Therapy and Patient Care

MAY 11-12, 2018 | NEW YORK CITY
This symposium will feature updated information on lymphoma biology, diagnosis, immunology, and genetics, and ongoing efforts to translate the scientific discoveries into novel treatment strategies for a variety of lymphomas. Faculty will review the current standard of care and present their own perspectives on how they treat various types of lymphomas. Participants will have the opportunity to discuss diagnostic and management cases, and how to incorporate biologic and genetic biomarkers into clinical practice and clinical trials.

**EDUCATIONAL OBJECTIVES**
- To provide up-to-date information on recent molecular diagnostic methods
- To provide up-to-date information on recent update on lymphoma pathology classification
- To provide up-to-date information on recent treatment options for patients with Hodgkin and non-Hodgkin lymphoma

**TARGET AUDIENCE**
The target audience includes medical and radiation oncologists, hematopathologists, scientists, and medical trainees involved in diagnosis, treatment, and biomedical research of lymphoma.
### INVITED FACULTY

**Ash A. Alizadeh, MD, PhD**  
Stanford University  
Stanford, CA

**Marc André, MD**  
Université Catholique de Louvain  
Belgium

**Stephen M Ansell, MD, PhD**  
Mayo Clinic  
Rochester, Minnesota

**Andreas Engert, MD**  
University Hospital of Cologne  
Germany

**Jude Fitzgibbon, PhD**  
Barts Cancer Institute  
England

**John P. Leonard, MD**  
Weill Cornell Medical College  
New York, NY

**Ronald Levy, MD**  
Stanford University  
Stanford, CA

**David Maloney, MD, PhD**  
Fred Hutchinson Cancer Research Center  
Seattle, WA

**Ari M. Melnick, MD**  
Weill Cornell Medical College  
New York, NY

**Franck Morschhauser, MD**  
Centre Hospitalier Régional Universitaire de Lille  
France

**Sattva S. Neelapu, MD**  
MD Anderson Cancer Center  
Houston, Texas

### Featuring National and International Experts

<table>
<thead>
<tr>
<th>Lecturer</th>
<th>Institution/Location</th>
</tr>
</thead>
</table>
| **Laura Pasqualucci, MD**                    | Columbia University  
New York, NY                                      |
| **Davide Rossi, MD, PhD**                     | The Institute of Oncology Research  
Switzerland                                         |
| **Stephen J. Schuster, MD**                  | The University of Pennsylvania  
Philadelphia, PA                                      |
| **John Seymour, MBBS, FRACP, PhD**           | Peter MacCallum Cancer Centre  
Australia                                                   |
| **Louis M. Staudt, MD, PhD**                  | National Cancer Institute  
Bethesda, MD                                               |
| **Catherine Thieblemont, MD**                | Saint-Louis Hospital  
France                                                        |
| **Irving Weissman, MD**                      | Stanford University  
Stanford, CA                                               |
| **Wyndham Wilson, MD, PhD**                   | National Cancer Institute  
Bethesda, MD                                               |
| **Thomas E. Witzig, MD**                      | Mayo Clinic  
Rochester, Minnesota                                      |
| **Wei Li Zhao, MD, PhD**                      | Shanghai Institute of Hematology  
China                                                       |

### SCIENTIFIC AGENDA

**FRIDAY, MAY 11, 2018**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session/Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:30 AM</td>
<td>REGISTRATION &amp; BREAKFAST</td>
</tr>
<tr>
<td>8:00 AM</td>
<td><strong>Department of Medicine Grand Rounds</strong></td>
</tr>
<tr>
<td></td>
<td>Disrupting the CD47-SIRPα Anti-phagocytic Axis to Treat Cancer</td>
</tr>
<tr>
<td></td>
<td>Irving Weissman, MD</td>
</tr>
<tr>
<td>9:00 AM</td>
<td><strong>State of the Lymphoma at Memorial Sloan Kettering</strong></td>
</tr>
<tr>
<td></td>
<td>Anas Younes, MD</td>
</tr>
<tr>
<td>9:45 AM</td>
<td><strong>SESSION I</strong></td>
</tr>
<tr>
<td></td>
<td>Advances and State of the Art in Clinical Care-1</td>
</tr>
<tr>
<td></td>
<td>MODERATOR Andrew D. Zelenetz, MD, PhD</td>
</tr>
<tr>
<td>9:45 AM</td>
<td><strong>Diffuse Large B Cell Lymphoma (DLBCL)</strong></td>
</tr>
<tr>
<td></td>
<td>Andrew D. Zelenetz, MD, PhD</td>
</tr>
<tr>
<td>10:00 AM</td>
<td><strong>T Cell Lymphoma</strong></td>
</tr>
<tr>
<td></td>
<td>Steven M. Horwitz, MD</td>
</tr>
<tr>
<td>10:15 AM</td>
<td><strong>Mantle Cell Lymphoma</strong></td>
</tr>
<tr>
<td></td>
<td>John P. Leonard, MD</td>
</tr>
<tr>
<td>10:30 AM</td>
<td><strong>MCL Trials at MSKCC</strong></td>
</tr>
<tr>
<td></td>
<td>Anita Kumar, MD</td>
</tr>
<tr>
<td>10:45 AM</td>
<td><strong>HIV Lymphoma</strong></td>
</tr>
<tr>
<td></td>
<td>Ariela Noy, MD</td>
</tr>
<tr>
<td>11:00 AM</td>
<td><strong>Panel Discussion</strong></td>
</tr>
<tr>
<td></td>
<td>Session I Faculty &amp; John P. Leonard, MD</td>
</tr>
<tr>
<td>11:30 AM</td>
<td><strong>BREAK</strong></td>
</tr>
<tr>
<td>11:45 AM</td>
<td><strong>SESSION II</strong></td>
</tr>
<tr>
<td></td>
<td>Advances and State of the Art in Clinical Care-2</td>
</tr>
<tr>
<td></td>
<td>MODERATOR Craig H. Moskowitz, MD</td>
</tr>
<tr>
<td>11:45 AM</td>
<td><strong>Follicular Lymphoma (FL)</strong></td>
</tr>
<tr>
<td></td>
<td>John Seymour, MBBS, FRACP, PhD</td>
</tr>
<tr>
<td>12:00 PM</td>
<td><strong>Hodgkin Lymphoma (HL)</strong></td>
</tr>
<tr>
<td></td>
<td>Andreas Engert, MD</td>
</tr>
<tr>
<td>12:15 PM</td>
<td><strong>HL Trials at MSKCC</strong></td>
</tr>
<tr>
<td></td>
<td>Alison J. Moskowitz, MD</td>
</tr>
<tr>
<td>12:30 PM</td>
<td><strong>Marginal Zone Lymphoma</strong></td>
</tr>
<tr>
<td></td>
<td>Catherine Thieblemont, MD</td>
</tr>
<tr>
<td>12:45 PM</td>
<td><strong>Double Hit Lymphoma</strong></td>
</tr>
<tr>
<td></td>
<td>Wyndham Wilson, MD</td>
</tr>
<tr>
<td>1:00 PM</td>
<td><strong>Panel Discussion</strong></td>
</tr>
<tr>
<td></td>
<td>Session II Faculty &amp; Marc André, MD</td>
</tr>
<tr>
<td>1:30 PM</td>
<td><strong>LUNCH</strong></td>
</tr>
</tbody>
</table>

*Space is limited and RSVP is required during course registration.*

**Adult BMT Luncheon (1:30-2:15 PM)**

*Are CARs Over Taking Transplant in Lymphoma*
#MSKLyphomaCME
SESSION VII

Immune Therapy

M. Lia Palomba, MD

1:15 PM  CAR T-cell: Transcend Study
          David Maloney, MD, PhD

1:30 PM  CAR T-cell: ZUMA-1 Study
          Sattva S. Neelapu, MD

1:45 PM  CAR T-cell: Juliet Study
          Stephen J. Schuster, MD

2:00 PM  New Approaches
          Renier J. Brentjens, MD, PhD

2:15 PM  Immune Checkpoint Inhibitors
          Stephen M Ansell, MD, PhD

2:30 PM  Panel Discussion
          Session VII Faculty

3:00 PM  BREAK

SESSION VIII

CNS Lymphoma

Paul A. Hamlin, MD

3:15 PM  How I Treat CNS Lymphoma at the NCI
          Wyndham Wilson, MD, PhD

3:30 PM  How I Treat CNS Lymphoma at
          Memorial Sloan Kettering
          Christian Grommes, MD

3:45 PM  Panel Discussion
          Session VIII Faculty

4:00 PM  SYMPOSIUM ADJOURN

REGISTRATION FEES

<table>
<thead>
<tr>
<th></th>
<th>EARLY*</th>
<th>GENERAL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Physicians (MDs, PhDs and DOs)</td>
<td>$350</td>
<td>$400</td>
</tr>
<tr>
<td>Nurses, PAs and Other Healthcare Professionals</td>
<td>$150</td>
<td>$200</td>
</tr>
<tr>
<td>Residents and Fellows</td>
<td>$100</td>
<td>$150</td>
</tr>
<tr>
<td>Industry Professionals**</td>
<td>$650</td>
<td>$700</td>
</tr>
</tbody>
</table>

*Early registration available until March 31, 2018

**Industry professionals may attend CME activities for their own education. Marketing, sales, and promotion of products and services is strictly prohibited at MSK CME activities.

Register Online:
www.mskcc.org/LymphomaCourse

Registration includes continental breakfast, lunch, and refreshment breaks. Please contact cme@mskcc.org at least one week prior to the course if you have any special dietary needs.

- 30% Discounted Rate for MSK Alumni and MSK Alliance Members: MSK offers a 30% discounted rate to all MSK Alumni and MSK Alliance members to attend a CME course. Please contact cme@mskcc.org for a promotion code or more information.
- MSK Staff Registration: Registration is complimentary for MSK staff. However, you must register online: www.mskcc.org/LymphomaCourse

ACCREDITATION STATEMENT
MSK is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

AMA CREDIT DESIGNATION STATEMENT
MSK designates this live activity for a maximum of 16.00 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

FACULTY DISCLOSURE
It is the policy of MSK to make every effort to insure balance, independence, objectivity, and scientific rigor in all continuing medical education activities which it provides as an ACCME accredited provider. In accordance with ACCME guidelines and standards, all faculty participating in an activity provided by MSK are expected to disclose any significant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services which are discussed by the faculty members in an educational presentation. As required by the ACCME, when an unlabeled use of a commercial product or an investigational use not yet approved for any purpose is discussed during an educational activity, MSK requires the speaker to disclose that the product is not labeled for the use discussed or that the product is still investigational.
MASTERCCLASS IN
LYMPHOMA PATHOLOGY

MAY 12-13, 2018

This one and half day course will provide a comprehensive review of new entities and challenging areas in the new 2017 WHO Classification of Lymphoid Neoplasms using case-based examples. The course is designed as an interactive slide seminar using microscope based teaching and will be limited to 30 participants.